Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, par value $.001
-
Shares outstanding
-
65.8M
-
Number of holders
-
170
-
Total 13F shares, excl. options
-
73.6M
-
Shares change
-
-328K
-
Total reported value, excl. options
-
$1.34B
-
Value change
-
-$25.5M
-
Put/Call ratio
-
3.2
-
Number of buys
-
88
-
Number of sells
-
-84
-
Price
-
$18.15
Significant Holders of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) as of Q1 2025
219 filings reported holding CLDX - Celldex Therapeutics, Inc. - Common Stock, par value $.001 as of Q1 2025.
Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) has 170 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 73.6M shares
.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (8.35M shares), Kynam Capital Management, LP (6.5M shares), BlackRock, Inc. (5.52M shares), FMR LLC (5.38M shares), VANGUARD GROUP INC (3.9M shares), EVENTIDE ASSET MANAGEMENT, LLC (3.75M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.41M shares), COMMODORE CAPITAL LP (3.2M shares), Bellevue Group AG (3.07M shares), and STATE STREET CORP (2.81M shares).
This table shows the top 170 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.